Angion Biomedica Corp.
51 Charles Lindbergh Blvd.
Tel: (516) 326-1200
11 articles with Angion Biomedica Corp.
Repairing a damaged organ in order to allow an individual to have a healthier life, as well as a greater quality of life, could soon be a reality as New York-based Angion Biomedica Corp. moves toward completing clinical trials of its lead asset.
Angion Biomedica and Sinovant Sciences Enter into Collaboration and License Agreement to Develop BB3 in Greater China
Angion Biomedica and Sinovant Sciences today announced a collaboration and license agreement for BB3, Angion's investigational small molecule mimetic of hepatocyte growth factor (HGF), in the People's Republic of China, Hong Kong, Macau, and Taiwan (Greater China).
Angion Biomedica Corp. Exclusively In-Licenses Aldosterone Synthase Inhibitors From ElexoPharm GmbH Complementing Its Ongoing Program In Chronic Kidney Disease
Angion Biomedica Corp.'s Phase 2 “GUARD” Clinical Trial Of BB3 In Acute Kidney Injury (AKI) Underway; Complements Ongoing Phase 3 Study In Renal Transplant Recipients With Delayed Graft Function (DGF)
Angion Biomedica Corp. To Present Clinical And Preclinical Data At The Upcoming American Society of Nephrology Conference In San Diego
Angion Biomedica Corp. Advances BB3 Into Pivotal Phase 3 Clinical Trial In Renal Transplant Patients With Delayed Graft Function
Angion Biomedica Corp. Receives Fast Track and Orphan Drug Product Designations from FDA for its Lead Therapeutic, BB3
Angion Biomedica Corp. Has Signed Licensing Option With Memorial Sloan-Kettering Cancer Center For Novel Vaccine Platform